Real-time · AI · Cross-signal

H1 just raised. Here's exactly what to do next.

Who to reach, what to say, and why now — on H1, plus every funding round, exec hire, and M&A move that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your plan Request a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.

✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.

✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.

✕Clay enriches lists you built — No live signal of its own, no who or when.

✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.

Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

Healthcare Data Platform H1 Raises $12.9M Series A Led by Menlo Ventures

PRIVATEApr 22, 2020•about 6 years ago

Amount Raised

$12 Million

Round Type

series a

Description

H1, a provider of data driven solutions for the healthcare industry, announced today the completion of its first institutional funding round. Menlo Ventures led the $12.9 million Series A, joined by Novartis dRx, Y Combinator, Baron Davis Enterprises, ClearPoint Investment Partners, Jeff Hammerbacher, Liquid 2 Ventures, and Underscore VC. Greg Yap, partner at Menlo Ventures, will join H1's board of directors.

Company Information

Company

About

On Tuesday, the company announced a $100 million Series C round. Katz chalks up the size of this round to growth in revenue over the past year – the company is reporting about a 250% increase in annual recurring revenue. The company has about 100 clients, says Katz, including top pharma companies like Novartis and AstraZeneca. Pauline Yang, a partner at Altimeter Capital, said that the company is also starting to unlock use cases for all that data, which is one reason Altimeter was attracted to H1. “The company saw incredible traction and growth with its first use case of helping pharma and life sciences identify key opinion leaders,” she told TechCrunch. The nature of the data the company has collected has started to shift. This year, however, the company has allowed physicians to start to “enhance” their own profiles. And, in the long-term, that user-generated data is one way the company might cement it’s place in the medical professional ecosystem. “Life science companies are hungry for data,” said Yang. “The H1 platform combines data from public, proprietary, and private sources – which enables H1 to uniquely unlock value. ”Over the course of this round, H1 has plans to sell to more pharma and life sciences companies by doubling down on go-to-market efforts.

Related People

Suggested for you

2 contacts

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for H1's next move

Learn about Strategic plan

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Watching H1? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demo Choose your plan